Fairvalue-Calculator Fairvalue-Calculator
EN DE

EASY BIO,Inc. (353810) Fair Value & Analysis

Consumer Non-Cyclicals · KR · Market cap 223B KRW

Price6,250 KRW
Fair Value16,375 KRW
Upside+162.0%
Quality92/100
Evidence: High Range 12,028 KRW – 46,408 KRW

Fair value as of: Jun 25, 2026

Analysis

EASY BIO,Inc. (353810) currently trades at 6,250 KRW, while our model-based Fair Value estimate is 16,375 KRW — implying the stock looks roughly 162.0% undervalued today. We read business quality at 92/100 (high quality), in the Consumer Non-Cyclicals sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

EASY BIO,Inc. provides specialized piglet feed and feed additives solutions in South Korea and internationally. The company was founded in 2020 and is based in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

FB (FB) -10% URC (URC) -23% MONDE (MONDE) -84% CNPF (CNPF) +110% DNL (DNL) +40% RFM (RFM) +93%

Frequently asked questions

Is EASY BIO,Inc. (353810) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 16,375 KRW versus a price of 6,250 KRW — about +162% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 353810?
Our 21-model fair value for EASY BIO,Inc. is 16,375 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 6,250 KRW.
What is the quality score of 353810?
EASY BIO,Inc. has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.